Benjamin Brigant

Benjamin Brigant

Auto-generated profile, based on publicly available information

Benjamin Brigant

Department of Clinical Research and Molecular Medicine (IKOM), Faculty of Medicine and Health Sciences (MH), Norwegian University of Science and Technology (NTNU), Trondheim, Norway

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JCJerry Chen
Jerry Chen
RFRabih Abou Farraj
Rabih Abou Farraj
DLDaniel Limonta
Daniel Limonta
SDSeyed amirhossein tabatabaei dakhili
Seyed amirhossein tabatabaei dakhili
EKEvan M. Kerek
Evan M. Kerek
BHBasil P. Hubbard
Basil P. Hubbard
The emergence of severe acute respiratory syndrome coronavirus 2, the causative agent of coronavirus disease 2019, has resulted in the largest pandemic in recent history. Current therapeutic strategies to mitigate this disease have focused on the development of vaccines and on drugs that inhibit the viral 3CL protease or RNA-dependent RNA polymerase enzymes. A less-explored and potentially complementary drug target is Nsp15, a uracil-specific RNA endonuclease that shields coronaviruses and other nidoviruses from mammalian innate immune defenses. Here, we perform a high-throughput screen of over 100,000 small molecules to identify Nsp15 inhibitors. We characterize the potency, mechanism, selectivity, and predicted binding mode of five lead compounds. We show that one of these, IPA-3, is an irreversible inhibitor that might act via covalent modification of Cys residues within Nsp15. Moreover, we demonstrate that three of these inhibitors (hexachlorophene, IPA-3, and CID5675221) block severe acute respiratory syndrome coronavirus 2 replication in cells at subtoxic doses. This study provides a pipeline for the identification of Nsp15 inhibitors and pinpoints lead compounds for further development against coronavirus disease 2019 and related coronavirus infections.

1 August 2025 in Non-coding RNA Research
Verified
Journal Article
Open access
EBEmma Brisot
Emma Brisot
PLPierre-Marie Leprêtre
Pierre-Marie Leprêtre
EHEya Hamza
Eya Hamza
OFOphélie Fourdinier
Ophélie Fourdinier
BBBenjamin Brigant
Benjamin Brigant
Laurent MetzingerLaurent Metzinger
Laurent Metzinger
Chronic kidney disease (CKD) poses a significant threat, with increased rates of cardiovascular and all-cause mortality. Anemia, common in CKD, is associated with accumulation of uremic toxins in the bloodstream. We previously demonstrated that the uremic toxin indoxyl sulfate (IS) impacts the regulation of erythropoiesis in cellular and preclinical CKD models. Here, the role of non-coding RNAs in this toxic effect was evaluated. The effect of IS on microRNA expression was measured in human erythropoietic cell line UT7/EPO, using nanostring. We found a significant increase of miR-223 in cells treated with IS. This finding was further validated in human primary CD34+ cells, a more physiological model for human erythropoiesis. Finally, serum levels of miR-223 correlated with representative uremic toxins, including IS, in patients with various stages of CKD, and also with endothelial dysfunction markers, indicating a link with vascular damage. These correlations varied according to erythropoietin treatment and dialysis. These findings suggest that miR-223 may play a role in the development of anemia in CKD. Further investigation into the involvement of miR-223 in erythropoiesis is needed for a better understanding of the mechanisms underlying anemia in CKD and the potential role of uremic toxins. Ultimately, this may open up new therapeutic possibilities for the management of anemia in CKD.

4 July 2026 in Osteoarthritis and Cartilage Open
Verified
Journal Article
Open access
BBBenjamin Brigant
Benjamin Brigant
KRKashif Rasheed
Kashif Rasheed
DODiana Carolina Ortega
Diana Carolina Ortega
ETErlend Tande
Erlend Tande
SSShiquan Sun
Shiquan Sun
VBVictor Boyartchuk
Victor Boyartchuk
CD5 antigen-like (CD5L) protein is a scavenger receptor involved in inflammation control and enriched in the synovial fluid and membranes of osteoarthritis (OA) patients. Although increased CD5L levels have been associated with OA pathology, its direct role in chondrocytes and contribution to cartilage degeneration remain unknown. We investigated the impact of CD5L on human chondrocytes in the context of OA. We compared CD5L mRNA levels in primary chondrocytes between OA patients and unaffected controls. We also measured CD5L levels in two chondrocyte cell lines under conditions mimicking OA. RNAseq was performed to determine the effects of increasing CD5L expression on the chondrocyte transcriptome. Finally, we studied the influence of CD5L levels on chondrocyte survival by depleting or overexpressing CD5L in chondrocyte cell lines. CD5L transcript levels were higher in primary chondrocytes from OA patients than in those from controls. Treatment with the pro-inflammatory cytokine IL1β or doxorubicin further induced CD5L expression in primary and cultured chondrocytes. Transcriptomic analysis revealed a correlation between high CD5L transcript levels and expression of genes involved in programmed cell death, inflammation, and differentiation. CD5L knockout increased survival of doxorubicin-treated chondrocytes and reduced apoptosis marker levels compared to non-targeting controls. Our data indicate that CD5L plays an important role in regulating chondrocyte cell death. CD5L expression levels are high in chondrocytes from OA patients, and decreasing CD5L expression reduces chondrocyte apoptosis induction in vitro. CD5L is therefore a potential target for OA management.